Policlinico Gemelli and Palantir Technologies Partner to Use AI to Advance Data Science for Healthcare
8.9.2023 13:59:00 EEST | Business Wire | Press release
Palantir Technologies Inc. (NYSE: PLTR) (“Palantir”) and Gemelli Generator Real World Data (RWD), a research facility of Fondazione Policlinico Universitario A. Gemelli IRCCS (“Policlinico Gemelli”), today announced a partnership to implement digital medicine research solutions that leverage artificial intelligence to improve patient care and health outcomes.
Policlinico Gemelli’s digital research center, Generator RWD, will utilize Palantir Foundry as one of the key enabling platforms to manage the full scale and complexity of healthcare data. Foundry’s AI capabilities will be utilized to generate Real World Evidence in support of clinical and translational research aimed at drug and indication discovery, improved patient care, and the development of digital medicine solutions for healthcare research in Italy and within their partnerships at global scale.
Palantir’s software will boost the capabilities of Generator RWD and its partner network as they continue in their quest to strengthen the exploitation of data to gain new insights in several healthcare research domains.
“Healthcare is transforming through the power of data and AI, and this trend will only accelerate. More and more of the industry is wielding this power to discover novel therapies, improve patient care and increase treatment efficiency and effectiveness,” said Andrea Galvagni, Head of Italy at Palantir. “At Palantir, we are proud to support world-leading institutions such as Policlinico Gemelli by providing them with the technology they need to achieve their most critical missions.”
"Real World Evidence is constantly gaining traction in support of research in healthcare. By integrating Foundry in the framework developed at Generator RWE, we aim at accelerating our research pipeline cycles to deliver faster and better outcomes,” said Vincenzo Valentini, Scientific Director of Gemelli Generator Research Facility.
"The added value of Palantir software and their deep skills in data-driven innovation will enrich the suite of products and services we are delivering within co-creation projects with our industrial partners," said Alfredo Cesario, CEO of Gemelli Digital Medicine & Health.
About Palantir Technologies Inc.
Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.
About Policlinico Gemelli
Gemelli Generator is an innovative center with multidisciplinary skills, which originates from the awareness of the need for tools capable to collect, store and analyze the huge amount of data generated every day from heterogeneous sources, translating them into understandable and usable information while fully respecting the privacy, data integrity and intellectual property, for the benefit of all.
Gemelli Generator, built in collaboration with the Università Cattolica del Sacro Cuore, is one of the projects of the Gemelli Science and Technological Park (GSTeP) of the Fondazione Policlinico Universitario A. Gemelli IRCCS, with the aim to provide physicians and researchers with a wide ranging research facility.
To support diagnosis and treatment and clinical processes, Gemelli Generator offers Artificial Intelligence and Big Data processing services for the integration of clinical data and the development of predictive models; aiming at the clinical and scientific valorisation of the skills, processes and data of the Data Warehouse (DWH) of the Fondazione Policlinico Universitario A. Gemelli IRCCS, through advanced data extraction, collection and analysis services.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230908825834/en/
Contact information
Media Contacts
Palantir
Lisa Gordon
media@palantir.com
Policlinico Gemelli
Nicola Cerbino
nicola.cerbino@policlinicogemelli.it
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Third Quarter 2026 Results3.11.2026 23:30:00 EET | Press release
IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modestly as we continue to strengthen the business. We also generated strong cash flow through the first nine months of 2026 and recently completed our $500 million accelerated share repurchase program. The separation of Food Ingredients is progressing well, and we are on track with our timelin
2026–2027 World Branding Awards Honours Global “ Brand of the Year ” Winners at Hampton Court Palace3.11.2026 22:00:00 EET | Press release
The World Branding Awards returned to honour the brands that continue to set the benchmark for excellence. The 2026–2027 World Branding Awards Ceremony took place at the iconic Hampton Court Palace, marking the 21st edition of the awards. Set within the grandeur of a historic venue, the prestigious event brought together guests from across the globe for a memorable celebration. The evening was hosted by the acclaimed BBC presenter, Hannah Gray, and was further enriched by a keynote presentation from renowned speaker Adrian Webster. Earning a World Branding Awards remains a highly distinguished achievement. Winners are determined through a rigorous evaluation process encompassing brand valuation, consumer market research, and public online voting. This year, over 105,000 consumers took part in the voting process, and more than 2,000 brands from 62 countries were nominated. Of these, less than 10 brands from each country were declared the “Brand of the Year” across the Global, Regional,
Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 20:05:00 EET | Press release
Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisition of Rosewood London reflects Gencom’s conviction in the market and serves as a strategic entry point into Europe. The transaction further enhances the firm’s assemblage
SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 17:52:00 EET | Press release
His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 17:03:00 EET | Press release
BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom